DURECT Corporation (DRRX) Receiving Somewhat Positive Media Coverage, Report Finds

News headlines about DURECT Corporation (NASDAQ:DRRX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. DURECT Corporation earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 46.6821249866162 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Shares of DURECT Corporation (NASDAQ:DRRX) traded up $0.06 on Friday, hitting $1.15. The company had a trading volume of 1,818,500 shares, compared to its average volume of 714,109. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.57 and a current ratio of 1.67. DURECT Corporation has a twelve month low of $0.74 and a twelve month high of $2.17.

DURECT Corporation (NASDAQ:DRRX) last issued its earnings results on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.09. The business had revenue of $20.75 million for the quarter, compared to analyst estimates of $5.09 million. DURECT Corporation had a negative return on equity of 419.65% and a negative net margin of 62.57%. equities research analysts expect that DURECT Corporation will post -0.14 EPS for the current year.

DRRX has been the topic of a number of analyst reports. HC Wainwright reiterated a “hold” rating on shares of DURECT Corporation in a report on Thursday, November 2nd. ValuEngine lowered DURECT Corporation from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 21st. Laidlaw reduced their price target on DURECT Corporation from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Friday, October 20th. Finally, Stifel Nicolaus lowered DURECT Corporation from a “buy” rating to a “hold” rating in a research note on Friday, October 20th.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://sportsperspectives.com/2017/11/24/durect-corporation-drrx-receiving-somewhat-positive-media-coverage-report-finds.html.

DURECT Corporation Company Profile

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Insider Buying and Selling by Quarter for DURECT Corporation (NASDAQ:DRRX)

Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply